UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

June 520, 2013

Date of Report

~~May~~June 3114, 2013

(Date of earliest event reported)

BIOZOOM, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-53678	26-0370478
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Wilhelmshoeher Allee 273A

Kassel, Germany, 34131

(Address of principal executive offices, including zip code)

800-882-1683

(Registrant’s telephone number, including area code)

N/A

(Former name, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Item 51.0201 ENTRY ~~DEPARTURE~~INTO OFA ~~DIRECTORS~~MATERIAL ORDEFINITIVE ~~CERTAIN OFFICERS~~AGREEMENT.

On June 514, 2013, Msthe registrant’s wholly owned subsidiary, Biozoom Technologies, Inc. ~~Sarah~~exercised ~~Deutsch~~its ~~resigned~~option, aspursuant to its February 28, 2013 joint venture agreement with Opsolution GmbH, a German company, to acquire 19.9% of Opsolution GmbH for $9,950. The foregoing description of the ~~assistant~~Exercise ~~secretary~~Agreement and ~~member~~the ofterms thereof are qualified in their entirety by the ~~Board~~full text of ~~Directors~~such ofagreement, ~~Biozoom~~which is filed as Exhibit 10.1 to, ~~Inc~~and incorporated by reference in, this report. A copy of the press release that discusses this matter is filed as Exhibit 99.1 to, and incorporated by reference in, this report.

ITEM 89.01 ~~OTHER~~ FINANCIAL ~~EVENTS.On~~STATEMENTS ~~May~~AND ~~31, 2013, the registrant Biozoom, Inc~~EXHIBITS.'s wholly owned subsidiary, Biozoom Technologies, Inc. (the “Company”), entered into a Scientific Advisory Board Consulting Agreement with Prof. Dr. Dr. Jürgen Lademann. Under the agreement, Prof. Dr. Dr. Lademann agreed to provide consulting services related to the field of dermatology up to twelve (12) days per year, attend meetings with other Scientific Advisory Board members, and earn 25,000 restricted common shares of the registrant's common stock 180 days after execution of the agreement, as well as an option to purchase 25,000 restricted common shares of the registrant's common stock each quarterly period following execution, at the closing market price on the first day of such period. The agreement has an initial term of 360 days, is renewable for successive one-year periods upon mutual agreement of the parties, and can be terminated by either party after providing the other 90 days notice.

~~SIGNATURES~~Exhibits

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit No.

Description

10.1

Exercise Agreement, dated June 14, 2013.

99.1

Press Release, dated June 14, 2013.

SIGNATURES

Dated: June 5, 2013	BIOZOOM, INC.
	By:	/s/ Hardy Hoheisel Name: Hardy Hoheisel Title: Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: June 20, 2013	BIOZOOM, INC.

	By:	/s/ Hardy Hoheisel Name: Hardy Hoheisel Title: Chief Executive Officer

Exhibit No.		Description
10.1		Exercise Agreement, dated June 14, 2013.
99.1		Press Release, dated June 14, 2013.

Filing Compare · Biozoom, Inc.